KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Exchange Rate Effect (2016 - 2025)

Historic Exchange Rate Effect for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $2.8 million.

  • Resmed's Exchange Rate Effect rose 10960.43% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $46.2 million, marking a year-over-year increase of 30179.83%. This contributed to the annual value of $25.8 million for FY2025, which is 160081.44% up from last year.
  • Latest data reveals that Resmed reported Exchange Rate Effect of $2.8 million as of Q4 2025, which was up 10960.43% from -$71000.0 recorded in Q3 2025.
  • In the past 5 years, Resmed's Exchange Rate Effect registered a high of $35.6 million during Q2 2025, and its lowest value of -$28.8 million during Q4 2024.
  • Over the past 5 years, Resmed's median Exchange Rate Effect value was -$140000.0 (recorded in 2023), while the average stood at $303500.0.
  • Its Exchange Rate Effect has fluctuated over the past 5 years, first plummeted by 443761.06% in 2022, then skyrocketed by 2747596.9% in 2025.
  • Over the past 5 years, Resmed's Exchange Rate Effect (Quarter) stood at -$270000.0 in 2021, then soared by 4140.74% to $10.9 million in 2022, then dropped by 22.86% to $8.4 million in 2023, then crashed by 442.32% to -$28.8 million in 2024, then soared by 109.6% to $2.8 million in 2025.
  • Its Exchange Rate Effect was $2.8 million in Q4 2025, compared to -$71000.0 in Q3 2025 and $35.6 million in Q2 2025.